1
|
Ding Y, Mullapudi B, Torres C, Mascariñas E, Mancinelli G, Diaz AM, McKinney R, Barron M, Schultz M, Heiferman M, Wojtanek M, Adrian K, DeCant B, Rao S, Ouellette M, Tsao MS, Bentrem DJ, Grippo PJ. Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway. Nutrients 2018; 10:nu10091289. [PMID: 30213082 PMCID: PMC6163264 DOI: 10.3390/nu10091289] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Revised: 09/06/2018] [Accepted: 09/07/2018] [Indexed: 12/12/2022] Open
Abstract
Pancreatic cancer remains a daunting foe despite a vast number of accumulating molecular analyses regarding the mutation and expression status of a variety of genes. Indeed, most pancreatic cancer cases uniformly present with a mutation in the KRAS allele leading to enhanced RAS activation. Yet our understanding of the many epigenetic/environmental factors contributing to disease incidence and progression is waning. Epidemiologic data suggest that diet may be a key factor in pancreatic cancer development and potentially a means of chemoprevention at earlier stages. While diets high in ω3 fatty acids are typically associated with tumor suppression, diets high in ω6 fatty acids have been linked to increased tumor development. Thus, to better understand the contribution of these polyunsaturated fatty acids to pancreatic carcinogenesis, we modeled early stage disease by targeting mutant KRAS to the exocrine pancreas and administered diets rich in these fatty acids to assess tumor formation and altered cell-signaling pathways. We discovered that, consistent with previous reports, the ω3-enriched diet led to reduced lesion penetrance via repression of proliferation associated with reduced phosphorylated AKT (pAKT), whereas the ω6-enriched diet accelerated tumor formation. These data provide a plausible mechanism underlying previously observed effects of fatty acids and suggest that administration of ω3 fatty acids can reduce the pro-survival, pro-growth functions of pAKT. Indeed, counseling subjects at risk to increase their intake of foods containing higher amounts of ω3 fatty acids could aid in the prevention of pancreatic cancer.
Collapse
Affiliation(s)
- Yongzeng Ding
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Bhargava Mullapudi
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Carolina Torres
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Emman Mascariñas
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Georgina Mancinelli
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Andrew M Diaz
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Ronald McKinney
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Morgan Barron
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Michelle Schultz
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Michael Heiferman
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Mireille Wojtanek
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Kevin Adrian
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Brian DeCant
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Sambasiva Rao
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | - Michel Ouellette
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Ming-Sound Tsao
- Toronto General Hospital, 200 Elizabeth St., Toronto, ON M5G 2C4, Canada.
| | - David J Bentrem
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
| | - Paul J Grippo
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Division of Gastroenterology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| |
Collapse
|
2
|
Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, Jung B. Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation. Oncotarget 2018; 8:3826-3839. [PMID: 27270652 PMCID: PMC5354798 DOI: 10.18632/oncotarget.9830] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Accepted: 05/14/2016] [Indexed: 01/05/2023] Open
Abstract
TGFβ has both tumor suppressive and tumor promoting effects in colon cancer. Also, TGFβ can affect the extent and composition of inflammatory cells present in tumors, contextually promoting and inhibiting inflammation. While colon tumors display intratumoral inflammation, the contributions of TGFβ to this process are poorly understood. In human patients, we found that epithelial loss of TGFβ signaling was associated with increased inflammatory burden; yet overexpression of TGFβ was also associated with increased inflammation. These findings were recapitulated in mutant APC models of murine tumorigenesis, where epithelial truncation of TGFBR2 led to lethal inflammatory disease and invasive colon cancer, mediated by IL8 and TGFβ1. Interestingly, mutant APC mice with global suppression of TGFβ signals displayed an intermediate phenotype, presenting with an overall increase in IL8-mediated inflammation and accelerated tumor formation, yet with a longer latency to the onset of disease observed in mice with epithelial TGFBR-deficiency. These results suggest that the loss of TGFβ signaling, particularly in colon epithelial cells, elicits a strong inflammatory response and promotes tumor progression. This implies that treating colon cancer patients with TGFβ inhibitors may result in a worse outcome by enhancing inflammatory responses.
Collapse
Affiliation(s)
- Daniel R Principe
- University of Illinois College of Medicine, Urbana-Champaign, IL, USA
| | - Brian DeCant
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Jonas Staudacher
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Dominic Vitello
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Riley J Mangan
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Elizabeth A Wayne
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.,Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Emman Mascariñas
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Andrew M Diaz
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Jessica Bauer
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Ronald D McKinney
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Khashayarsha Khazaie
- Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - Boris Pasche
- Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA
| | - David W Dawson
- Department of Pathology and Laboratory Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Hidayatullah G Munshi
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.,Department of Medicine, Northwestern University, Chicago, IL, USA
| | - Paul J Grippo
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| | - Barbara Jung
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
| |
Collapse
|
3
|
Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Res 2016; 76:2525-39. [PMID: 26980767 DOI: 10.1158/0008-5472.can-15-1293] [Citation(s) in RCA: 141] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 02/12/2016] [Indexed: 02/07/2023]
Abstract
In early pancreatic carcinogenesis, TGFβ acts as a tumor suppressor due to its growth-inhibitory effects in epithelial cells. However, in advanced disease, TGFβ appears to promote tumor progression. Therefore, to better understand the contributions of TGFβ signaling to pancreatic carcinogenesis, we generated mouse models of pancreatic cancer with either epithelial or systemic TGFBR deficiency. We found that epithelial suppression of TGFβ signals facilitated pancreatic tumorigenesis, whereas global loss of TGFβ signaling protected against tumor development via inhibition of tumor-associated fibrosis, stromal TGFβ1 production, and the resultant restoration of antitumor immune function. Similarly, TGFBR-deficient T cells resisted TGFβ-induced inactivation ex vivo, and adoptive transfer of TGFBR-deficient CD8(+) T cells led to enhanced infiltration and granzyme B-mediated destruction of developing tumors. These findings paralleled our observations in human patients, where TGFβ expression correlated with increased fibrosis and associated negatively with expression of granzyme B. Collectively, our findings suggest that, despite opposing the proliferation of some epithelial cells, TGFβ may promote pancreatic cancer development by affecting stromal and hematopoietic cell function. Therefore, the use of TGFBR inhibition to target components of the tumor microenvironment warrants consideration as a potential therapy for pancreatic cancer, particularly in patients who have already lost tumor-suppressive TGFβ signals in the epithelium. Cancer Res; 76(9); 2525-39. ©2016 AACR.
Collapse
Affiliation(s)
- Daniel R Principe
- University of Illinois College of Medicine, Urbana-Champaign, Illinois
| | - Brian DeCant
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois
| | - Emman Mascariñas
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois
| | - Elizabeth A Wayne
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois. Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Andrew M Diaz
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois
| | - Naomi Akagi
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois
| | - Rosa Hwang
- Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Boris Pasche
- Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina
| | - David W Dawson
- Department of Pathology and Laboratory Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California
| | - Deyu Fang
- Department of Pathology, Northwestern University, Chicago, Illinois
| | - David J Bentrem
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Hidayatullah G Munshi
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Medicine, Northwestern University, Chicago, Illinois
| | - Barbara Jung
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
| | - Paul J Grippo
- Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
| |
Collapse
|
4
|
Abstract
With the establishment of outstanding rodent models of pancreatic neoplasia and cancer, there are now systems available for evaluating the role diet, dietary supplements, and/or therapeutic compounds (which can be delivered in the diet) play in disease suppression. Several outstanding reports, which demonstrate clear inhibition or regression of pancreatic tumors following dietary manipulations, represent a noticeable advancement in the field by allowing for the contribution of diet and natural and synthetic compounds to be identified. The real goal is to provide support for translational components that will provide true chemoprevention to individuals at higher risk for developing pancreatic cancer. In addition, administration of molecules with proven efficacy in an in vivo system will screen likely candidates for future clinical trials. Despite this growing enthusiasm, it is important to note that the mere one-to-one translation of findings in rodent models to clinical outcomes is highly unlikely. Thus, careful consideration must be made to correlate findings in rodents with those in human cells with full disclosure of the subtle but often critical differences between animal models and humans. Additional concern should also be placed on the approaches employed to establish dietary components with real potential in the clinic. This chapter is focused on procedures that provide a systematic design for evaluating dietary compounds in cell culture and animal models to highlight which ones might have the greatest potential in people. The general format for this text is a stepwise use of fairly well-known approaches covered briefly but annotated with certain considerations for dietary studies. These methods include administration of a compound or a diet, measuring the cellular and molecular effects (histology, proliferation, apoptosis, RNA and protein expression, and signaling pathways), measuring the level of certain metabolites, and assessing the stability of active compounds. Though this chapter is divided into in vitro and in vivo sections, it is not an implication as to the order of experiments but an endorsement for utilizing human cells to complement work in a rodent modeling system. The notion that cell culture can provide the basis for further in vivo work is an attractive starting point, though the lack of a response in a single cell type should not necessarily prevent diet studies in rodents. The advantage of cell culture over animal models is the human origin of these cells and the ease and directness of manipulating a single cell type (particularly when exploring mechanism of action in that cell). Of course, the full effect of a diet, diet supplement, or therapeutic can only be wholly appreciated in an intact living organism with similar anatomical and physiological relevance. Thus, both approaches are considered in this chapter as each can provide unique strengths to determining the effectiveness of various dietary compounds or supplements on pancreatic neoplasia and cancer.
Collapse
Affiliation(s)
- Emman Mascariñas
- Department of Surgery, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | | | | |
Collapse
|